Friday, 6 November 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 12, 2026

SK Hynix Joins the Nasdaq. But This Nasdaq-100 Semiconductor Stock Could Be an Even Better Buy for the Second Half of 2026.

View original at nasdaq.com
SK Hynix Joins the Nasdaq. But This Nasdaq-100 Semiconductor Stock Could Be an Even Better Buy for the Second Half of 2026. Key Points The memory chip shortage is one of the biggest bottlenecks for artificial intelligence (AI)…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • ASML has a virtual monopoly on extreme ultraviolet (EUV) machines.

    60% confidence
  • SK Hynix will never join the S&P 500 because it is a South Korean company, similar to Taiwan Semiconductor Manufacturing.

    60% confidence
  • Demand for SK Hynix memory chips is far outpacing supply, creating a multi-year runway for future growth that has propelled the company to a $1 trillion valuation.

    60% confidence
  • ASML is an even better Nasdaq-100 stock than SK Hynix for investors seeking a fundamental AI stock to buy and hold for at least five years.

    60% confidence
  • ASML is the better buy for folks with a long-term investing time horizon compared to memory stocks like SK Hynix.

    60% confidence
  • ASML doesn't design or manufacture chips; it produces advanced machines needed to perform the lithography step in semiconductor manufacturing.

    60% confidence
  • Stock Advisor's total average return is 929%, a market-crushing outperformance compared to 211% for the S&P 500.

    60% confidence
  • In Q1 2026, memory's share of ASML net system sales rose to 51% (from 42% in Q1 2025), while logic's share fell to 49% (from 58% in Q1 2025).

    60% confidence

Data points we hold from this source

Applied Materials, Inc. · forward pe ratio49.2 ratio
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com